Supplemental Figure 3 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Tumor PU-H71 retention at 24 hours post-injection (quantified by standard uptake value) is not explained by plasma radiotracer exposure (quantified by plasma AUC from 10 min to 4 h post-injection, see Methods), as indicated by Spearman Test R-value.